Prenatal to Postnatal Renal and Genitourinary Anomalies - Genetics, Management and Outcomes - A Joint Course with ISPD - Short Course
Date of Release: May 1, 2020
CME, General CEU's, P.A.C.E.® Expiration Date: May 1, 2023
NSGC Credits Expiration Date: May 01, 2022
www.acmgeducation.net
Overview of renal and genitourinary anomalies from prenatal presentation to pediatric outcomes.
Target Audience
All healthcare professionals interested in the diagnosis, management, treatment and prevention of genetic conditions and increasing their understanding of the genetic basis of common, chronic health problems affecting both children and adults will find the programming applicable to their practice
Agenda
Louise E. Wilkins-Haug, MD, PhD, FACMG Introductions and Overview
Anthony R. Gregg, MD, MBA, FACMG Prenatal Screening for Sex Chromosome Aneuploidy - Ambiguity, Discordance and First Steps in Management
Louanne Hudgins, MD, FACMG Fetal Cystic Kidneys: Prenatal and Postnatal Considerations
Louise E. Wilkins-Haug, MD, PhD, FACMG Sorting Out Posterior Urethral Valve Imposters
Ali G. Gharavi, MD Genome-wide Approaches for Diagnosis of Kidney and Urogenital Disorders
Learning Objectives
At the conclusion of this session, participants should be able to:
Presenters
Louise E. Wilkins-Haug, MD, PhD, FACMG
Division Director, Maternal Fetal Medicine and Reproductive Genetics
Brigham & Women's Hospital
Anthony R. Gregg, MD, MBA, FACMG
ACMG and ACMG Foundation Board of Directors
Chair of the Department of Obstetrics and Gynecology and Chief of Maternal Fetal Medicine at Baylor University Medical Center
Louanne Hudgins, MD, FACMG
Professor of Pediatrics, Division of Medical Genetics, Stanford University School of Medicine
Ali G. Gharavi, MD
Jay Meltzer Professor of Nephrology and Hypertension and serves as Chief of the Division of Nephrology at Columbia University Irving Medical Center
Financial Disclosures
Disclosure Statement
It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Disclosure must include financial relationships of the individual and those of their spouse/partner. Individuals who do not disclose will be disqualified from participating in a CME activity.
This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity. ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.
NOTE:
Has no relevant financial relationships to disclose.
Dr. Gharavi has disclosed that he is a consult for Astra Zeneca; has external grant/research support from
Renal Research Institute.
Educational Credit
Accreditation Statement
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE (Continuing Education for non-physicians): This activity has been approved for CE credits.*The certificate is accepted by the ABMGG for certification.
Genetic Counselor Credit
The National Society of Genetic Counselors (NSGC) has authorized American College of Medical Genetics to offer up to 4.5 Category 1 contact hours for this activity. The American Board of Genetic Counseling (ABGC) will accept CEUs earned at this program for the purposes of genetic counselor certification and recertification.
ACMG will report completed accredited sessions to NSGC for credit certificates on December 4, 2020, December 3, 2021 and July 8, 2022. Submissions outside of these parameters may incur a processing fee of $35.
P.A.C.E.® CEUs- Laboratory Directors and Laboratory Personnel
ACMG is approved as a provider of continuing education programs in the clinical laboratory sciences by the American Society for Clinical Laboratory Science (ASCLS) Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program. The American College of Medical Genetics and Genomics designates this OnDemand course for a maximum of 4.5 contact hours. ACMG is approved by the Florida Board of Clinical Laboratory Personnel as CE Provider #50-11878. This course is registered # 20-775394 with CEBroker. ACMG is approved by the California Department of Health Services through the ASCLS P.A.C.E.®
Claiming your Educational Credits
Complete the activity, score 80% or better on the post-test, and carefully complete the evaluation form.
HIPAA Compliance
The ACMG supports medical information privacy. While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the ACMG HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available on request.
Content Validation
ACMG follows the ACCME policy on Content Validation for CME activities, which requires:
Content Validation and Fair Balance
Off-label Uses of Products
When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.
Disclaimer
The ACMG does not endorse, or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.
© 2023 American College of Medical Genetics and Genomics. All rights reserved.